ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 529 for:    cutaneous [CONDITION] AND "lymphoma "[CONDITION]

AFM13 in Relapsed/Refractory Cutaneous Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03192202
Recruitment Status : Recruiting
First Posted : June 20, 2017
Last Update Posted : August 10, 2017
Sponsor:
Information provided by (Responsible Party):
Ahmed Sawas, Columbia University

Brief Summary:
The investigators plan to investigate AFM13 and evaluate its ability to facilitate and redirect the Natural Killer (NK) cells in eliminating CD30-positive lymphoma targets in the skin and, by inference, other organs involved by the lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma, T-Cell, Cutaneous Drug: AFM13 Phase 1 Phase 2

Detailed Description:

This is an open label, Phase Ib/IIa study designed to evaluate the biologic activity of AFM13 in patients with relapsed or refractory CD30-positive lymphomas with cutaneous involvement. Primary cutaneous CD30-positive lymphoproliferative disorders (LPD) represent a spectrum from lymphomatoid papulosis (LyP), to primary cutaneous anaplastic large cell lymphoma (C-ALCL), to transformed mycosis fungoides (TMF).

The most indolent form of primary cutaneous CD30-positive LPD is LyP, which is usually well controlled with low dose oral methotrexate, but control of the disease frequently requires life-long therapy. In contrast, TMF is an aggressive disease which does not have a standard of care, as patients are treated with various modalities of care with variable outcomes). The spectrum of other CD30-positive lymphomas with cutaneous presentation is very broad and involves systemic B and T cell lymphomas with various clinical behaviors.

Redirecting Natural Killer (NK) cells towards these CD30-positive malignancies through direct engagement with AFM13 is expected to induce tumor cell killing through NK cell-mediated and T cell-mediated cytotoxicity (i.e., cytotoxic T lymphocytes (CTL)).

The primary objective of this trial is to study the biologic and immunologic effects induced by the administration of various doses of AFM13, when given as a single agent.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study
Actual Study Start Date : July 17, 2017
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Cohort 1
1.5 mg/kg of AFM13 once weekly for weeks 1-8.
Drug: AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Other Name: AFM13 recombinant antibody

Experimental: Cohort 2
1.5 mg/kg of AFM13 three times per week for weeks 1-8.
Drug: AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Other Name: AFM13 recombinant antibody

Experimental: Cohort 3
0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
Drug: AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Other Name: AFM13 recombinant antibody

Experimental: Cohort 4
1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
Drug: AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Other Name: AFM13 recombinant antibody

Experimental: Cohort 5
7.0 mg/kg of AFM13 once weekly for weeks 1-8.
Drug: AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Other Name: AFM13 recombinant antibody

Experimental: Cohort 6
4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
Drug: AFM13
AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Other Name: AFM13 recombinant antibody




Primary Outcome Measures :
  1. Percentage of Intratumoral NK-cells and T-cells infiltration into tumors [ Time Frame: Up to 2 years ]
    Quantified by multiplex Immuno-histochemistry (IHC) using tissue samples

  2. Number of immune cells (NK cells, T cells, and others) in tumor and peripheral blood [ Time Frame: Up to 2 years ]
    Measured by multi-color flow cytometry and immunophenotyping technique

  3. Level of plasma cytokine production plus release in tumor and peripheral blood as a function of treatment [ Time Frame: Up to 2 years ]
    Elisa test will be used to measure cytokine levels


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Up to 2 years ]
    Incidence of Treatment-Emergent Adverse Events [Safety and Toxicity] broken down by adverse event and CTCAE v4.0 grade of each event.

  2. Overall Response Rate (ORR) [ Time Frame: Up to 2 years ]
    The sum of patients with partial responses and complete responses.

  3. Duration of Response (DOR) after treatment with AFM 13 [ Time Frame: Up to 2 years ]
    The time of initial response until documented tumor progression.

  4. Progression Free Survival (PFS) after treatment with AFM 13 [ Time Frame: Up to 2 years ]
    The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years
  • Histologically confirmed CD30-positive lymphoma with cutaneous involvement
  • Failure or intolerance to at least one prior therapy for the current disease
  • Presence of one or more cutaneous lesions (measuring at least 1 cm x 1 cm in size; if only one lesion is present it should be up to the investigator discretion to determine eligibility)
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Adequate organ and marrow function
  • Platelets ≥50,000/μL
  • Absolute neutrophil count ≥ 1,000/μL
  • Bilirubin < 1.5 x institutional upper limit of normal (ULN) or < 3 x ULN in patients with Gilbert's disease or liver involvement
  • Serum albumin ≥ 2.0 g/dL
  • Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) ≤2.5 × institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ≤ 5 x ULN
  • Creatinine≤1.5 x institutional ULN or estimated creatinine clearance of ≥45 mL/min by the Cockcroft-Gault equation or measured creatinine clearance >45 mL/min
  • Females of child bearing potential must have a negative serum pregnancy test with 7 days prior to first dose of treatment. Female patients of childbearing potential and all male partners must agree to use double barrier methods of contraception throughout the study period and for at least 30 days following investigational product discontinuation.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Any cancer-related therapy for the current disease within 2 weeks of screening (all supportive care measures are allowed)
  • Major surgery within 2 weeks prior to first dose of study drug
  • Evidence of active central nervous system (CNS) involvement
  • Requirement for systemic immunosuppressive therapy (e.g. Graft-versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drug)
  • Uncontrolled concurrent serious illness.
  • Concurrent malignancy or history of a previous malignancy within 3 years prior to first dose of the current study, unless curatively resected basal, squamous cell carcinoma of the skin, or cervical carcinoma in situ.
  • Active infections including hepatitis B carrier status, hepatitis C virus (HCV) infection (patients must have a negative Hepatitis B and Hepatitis C viral load at screening)
  • Known HIV-positive status
  • Any significant medical conditions, laboratory abnormality, or psychiatric illness that would exclude the subject from participation or interfere with study treatment, monitoring and compliance such as:
  • unstable angina pectoris, symptomatic congestive heart failure (New York Heart Association (NYHA) III or IV), myocardial infarction ≤ 6 months prior to first study drug, clinically significant and uncontrolled cardiac arrhythmia (e.g. atrial fibrillation/flutter ventricular cardiovascular physiology is allowed), cerebrovascular accidents ≤ 6 months before study drug start
  • severely impaired lung function
  • Serious, systemic infection requiring treatment ≤7 days before the first dose of study drug
  • Any severe, uncontrolled disease or condition which in the investigator's opinion, may put the subject at significant risk, may confound the study results, or impact the subject's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03192202


Contacts
Contact: Celeste Rojas 212-326-5720 lymphoma@cumc.columbia.edu

Locations
United States, New York
Center for Lymphoid Malignancies Recruiting
New York, New York, United States, 10019
Contact: Celeste Rojas    212-326-5720    lymphoma@cumc.columbia.edu   
Principal Investigator: Ahmed Sawas, MD         
Sponsors and Collaborators
Ahmed Sawas
Investigators
Principal Investigator: Ahmed Sawas Columbia University Medical Center Assistant Professor of Medicine

Responsible Party: Ahmed Sawas, Assistant Professor of Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT03192202     History of Changes
Other Study ID Numbers: AAAP4461
First Posted: June 20, 2017    Key Record Dates
Last Update Posted: August 10, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ahmed Sawas, Columbia University:
Lymphoma
Cutaneous Lymphoma
cutaneous T-cell lymphoma (CTCL)
CD30-Positive Cutaneous Lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Cutaneous
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs